Company profile
KetoSwiss AG
Due to our modern carb rich diets our brains rely predominantly on glucose,which can contribute to an energy deficiency in the brain and trigger migraine. KetoSwiss(KS) has developed a novel migraine preventative. Its active compound is an endogenous metabolite; a ketone body(KB), which is used by the brain as an alternative fuel to glucose, when glucose utilization or transport is limited. KBs are produced by the liver during fasting/carb restriction but have a short half-life. KS strives to bring human identical KBs back into our modern world. The product is patent backed & superior to any current competition. We can achieve infusion-like therapeutic ketosis with a single neutral tasting oral dose. Reaching just 10% of the migraineur target group in US,EU,Ca & J can deliver 1.8b revenue.
Source: startup.ch
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
